DBV Technologies at the Citizens JMP Life Sciences Conference
DBV Technologies, a rising star in the biopharmaceutical sector, is preparing to showcase its innovative approaches at an upcoming prestigious life sciences conference. This event serves as a vital platform for industry experts to exchange ideas and discuss advances in the field. Daniel Tassé, the Chief Executive Officer of DBV Technologies, is set to engage in a fireside chat that will delve into the company’s latest developments.
Leadership and Vision
Under the leadership of Daniel Tassé, DBV Technologies is on a mission to transform the treatment of food allergies. The fireside chat at the Citizens JMP Life Sciences Conference will highlight the company's unique commitment to addressing unmet medical needs through scientific innovation. With food allergies affecting millions, Daniel's insights are anticipated to resonate with both industry peers and stakeholders.
Highlighting Innovative Approaches
As a clinical-stage biopharmaceutical company, DBV Technologies is at the forefront of developing therapies that harness the potential of its proprietary VIASKIN® technology. This groundbreaking approach generously offers new hope for individuals suffering from food allergies through epicutaneous immunotherapy (EPIT™). By delivering therapeutic compounds directly through the skin, the VIASKIN® patch re-educates the immune system, promoting desensitization to allergens.
Transforming Patient Care
The ideal of transforming care for individuals with food allergies is not just a vision for DBV Technologies but a commitment grounded in ongoing clinical research. The company is actively enrolling participants in trials for its products aimed at young children, ensuring that treatment is aligned with their unique needs. This dedication showcases DBV's role in leading the charge against food allergies.
Event Participation and Live Access
The Citizens JMP Life Sciences Conference will take place in an engaging setting where industry leaders will converge. For those unable to attend, DBV Technologies is offering a live webcast of the fireside chat. It will also be accessible via the company's investor relations website, making it easier for interested parties to engage with the latest insights directly from the source. A replay will be available for 90 days post-event, providing ample opportunity for stakeholders to catch up.
The DBV Technologies Commitment
With a corporate headquarters in Châtillon and additional operations in North America, DBV Technologies exemplifies a global perspective while focusing on localized patient needs. The company’s shares are traded on the Euronext Paris, and its American Depositary Shares (ADS), representing five ordinary shares, trade on the Nasdaq under the ticker symbol DBVT. This reflects the company's robust international presence and stature within the biopharmaceutical community.
About DBV Technologies
DBV Technologies is on a path to revolutionize treatments for immunological conditions, particularly food allergies. Their innovative approach through the VIASKIN® patch technology is designed to alter the way allergies are treated by utilizing the body's natural immune responses. This mission aligns with a broader goal of addressing the urgent needs of those who face life-threatening allergies.
As millions of individuals and families navigate the complexities of food allergies, DBV Technologies remains diligent in its efforts to create safer environments and better treatments for this growing public health concern. The company actively engages in clinical trials, ensuring that their products effectively meet the needs of diverse populations.
Frequently Asked Questions
What is the focus of DBV Technologies?
DBV Technologies is focused on developing treatment options for food allergies and other immunologic conditions that require effective solutions.
Who will represent DBV Technologies at the conference?
Daniel Tassé, the Chief Executive Officer, will represent DBV Technologies during the fireside chat at the conference.
What technology does DBV Technologies utilize?
DBV Technologies uses its proprietary VIASKIN® patch technology, which is designed to treat food allergies through skin-based therapy.
How can I access the conference webcast?
The live webcast of the fireside chat will be available on the DBV Technologies investor relations website and will be accessible for 90 days post-event.
Where is DBV Technologies headquartered?
DBV Technologies is headquartered in Châtillon, France, with operations in North America located in Warren, New Jersey.
